{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:20:53Z","timestamp":1778538053955,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejca.2019.06.022","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T13:07:53Z","timestamp":1566306473000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon Kroll","family":"Bjerregaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.06.022_bib1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1055-9965.EPI-07-0152","article-title":"Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in\u00a0vivo","volume":"16","author":"Bataille","year":"2007","journal-title":"Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"10.1016\/j.ejca.2019.06.022_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2340\/00015555-2944","article-title":"Effect of age on melanoma risk, prognosis and treatment response","volume":"98","author":"Ribero","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2019.06.022_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cei.12875","article-title":"Considerations for successful cancer immunotherapy in aged hosts","volume":"187","author":"Hurez","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ejca.2019.06.022_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2019.06.022_bib5","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.ejca.2019.06.022_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol-Hematol"},{"key":"10.1016\/j.ejca.2019.06.022_bib7","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/annonc\/mdy228","article-title":"Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide","volume":"29","author":"Scotte","year":"2018","journal-title":"Ann Oncol: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.ejca.2019.06.022_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2019.06.022_bib9","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejca.2019.06.022_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jgo.2018.06.009","article-title":"Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper","volume":"10","author":"Bastiaannet","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ejca.2019.06.022_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.06.022_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-9966-33-30","article-title":"Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme","volume":"33","author":"Chiarion Sileni","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.06.022_bib13","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.06.022_bib14","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.06.022_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.06.022_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejca.2019.06.022_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.06.022_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.06.022_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received Nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.022_bib20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","article-title":"Impact of age on outcomes with immunotherapy for patients with melanoma","volume":"22","author":"Betof","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2019.06.022_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.06.022_bib22","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2006.09.0274","article-title":"Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint committee on cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial","volume":"25","author":"Schmidt","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.022_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11912-018-0656-3","article-title":"Melanoma immunotherapy in the elderly","volume":"20","author":"Orloff","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2019.06.022_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cei.12851","article-title":"Immune senescence: significance of the stromal microenvironment","volume":"187","author":"Masters","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ejca.2019.06.022_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2019.06.022_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jgo.2017.04.003","article-title":"Checkpoint inhibition and melanoma: considerations in treating the older adult","volume":"8","author":"Friedman","year":"2017","journal-title":"J Geriatr Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:25:06Z","timestamp":1760732706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919304149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":26,"alternative-id":["S0959804919304149"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.06.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}